10-Q: Accuray Reports Q1 Loss Amid Revenue Decline, Leadership Shift

Accuray Incorporated reported a significant net loss and revenue decrease in its first fiscal quarter, alongside a major organizational transformation and leadership changes.

Summary

• Net revenue for the three months ended September 30, 2025, decreased by 7% to $93.9 million from $101.5 million in the prior year.
• Products net revenue decreased by $11.2 million (23%) primarily due to lower shipments to China.
• Services net revenue increased by $3.6 million (7%) due to higher contract revenues from an increased installed base.
• Gross profit decreased by $7.9 million (23%) to $26.5 million, with gross profit margin falling to 28.3% from 33.9%.
• Operating expenses increased by 3% to $37.9 million, driven by higher general and administrative costs.
• Net loss significantly widened to $21.7 million ($0.18 per share) from $4.0 million ($0.04 per share) in the prior year.
• Interest expense surged to $8.1 million from $3.0 million, primarily due to higher interest payments and financing costs for Term Loan Facilities, including $2.3 million in non-cash paid-in-kind interest.
• A loss of $1.9 million was recorded from the change in fair value of warrant liability due to an increase in the common stock share price.
• The company initiated a cost-saving initiative, eliminating approximately 3% of its global workforce, resulting in a $1.5 million restructuring charge for severance and $1.3 million for third-party consulting.
• Cash and cash equivalents stood at $63.3 million as of September 30, 2025.
• Total remaining performance obligations amounted to $866.0 million, with 30% to 35% of the $803.7 million for open systems sales, upgrades, training, and other items expected to be recognized in the next 12 months.
• Approximately 27% of the $760.7 million open system sales contracts as of September 30, 2025, may never result in revenue due to long sales cycles and external factors.

Sentiment

Score: 3

Explanation: The company reported a significant increase in net loss and a decline in revenue and gross profit, indicating poor financial performance. While there are strategic initiatives like restructuring and new leadership, and positive operating cash flow, the immediate financial results, high debt costs, and persistent macroeconomic headwinds create a negative outlook. The substantial decline in backlog and ongoing risks further contribute to a low sentiment score.

Positives

• Services net revenue increased by 7% to $56.8 million, driven by growth in the installed base.
• Net cash provided by operating activities was $12.2 million for the quarter, a significant improvement from a $7.3 million use in the prior year.
• Income from equity method investment (JV) increased by $0.5 million, moving from a loss of $72 thousand to an income of $439 thousand.
• The company believes it has sufficient cash resources and anticipated cash flows to fund operations for at least the next 12 months.
• The company was in compliance with all covenants and requirements of its Financing Agreement as of September 30, 2025.

Negatives

• Total net revenue decreased by 7% to $93.9 million, primarily due to a 23% decline in products revenue.
• Net loss significantly widened to $21.7 million from $4.0 million in the prior year, representing a substantial increase in unprofitability.
• Gross profit decreased by 23% to $26.5 million, with the gross profit margin declining to 28.3% from 33.9% due to geographic and product sales mix, and tariff costs.
• Interest expense more than doubled to $8.1 million, largely due to higher interest payments and non-cash paid-in-kind interest on new Term Loan Facilities.
• A $1.9 million loss was recorded from the change in fair value of warrant liability.
• Sales to the China joint venture (JV) for products decreased significantly from $28.6 million to $8.8 million.
• The company recorded $2.8 million in restructuring charges related to a 3% global workforce reduction and third-party consulting.
• Net orders decreased by $23.7 million, primarily due to lower gross orders and an increase in age-outs, with no age-ins during the quarter.

Risks

• Ongoing global economic environment risks, including inflation, high interest rates, foreign currency exchange rate fluctuations, and tightening credit markets, could adversely affect business and customer financing.
• Geopolitical concerns (Russia-Ukraine, Middle East conflicts, US-China tensions, China anti-corruption campaign) and changes in government policy positions could negatively impact operations.
• Continued supply chain challenges and logistics costs are expected to adversely affect gross margins, net income (loss), and cash from operations through at least fiscal year 2026.
• Reduced budgets and lower capital deployment priority for radiotherapy equipment, along with longer customer installation timelines in the United States, are expected to negatively impact net revenue through fiscal year 2026.
• Significant tariff uncertainty, particularly related to U.S.-China trade, is expected to increase costs and adversely impact product sales in China through at least the first half of fiscal year 2026.
• Substantial indebtedness ($152.4 million outstanding borrowings, $18.0 million convertible notes) and restrictive covenants in the Financing Agreement could adversely affect financial condition and future financial results, with past non-compliance requiring waivers.
• The company's ability to achieve profitability depends on maintaining or increasing gross margins, which are currently declining.
• Reliance on single-source suppliers for critical components could harm the ability to meet demand in a timely and cost-effective manner, exacerbated by global supply chain disruptions and inflationary pressures.
• The long and variable sales and installation cycle for products (6-30 months for sales, up to 24 months for installation) makes revenues and cash flows volatile and difficult to predict, with a significant portion of open contracts potentially never converting to revenue.
• Dependence on key employees and the ability to attract and retain talent is critical, with competition for qualified personnel being intense.
• Disruption of critical information technology systems, cyberattacks, or other security breaches could harm business and financial condition, including risks related to AI integration.
• Failure to comply with legal or regulatory requirements related to privacy, cybersecurity, and data protection could result in proceedings, actions, or penalties.
• Continued consolidation in the healthcare industry could lead to pricing pressures and decreased average selling prices.
• Insufficient coverage and reimbursement from third-party payors for product procedures could adversely affect demand and revenue.
• The safety and efficacy of products for certain uses are not yet fully supported by long-term clinical data, posing risks if future studies show less effectiveness or complications.
• Failures or disruptions at third-party logistics providers could adversely impact business, leading to delays and higher costs.
• Potential claims of intellectual property infringement by third parties could result in significant expenses, litigation, or restrictions on product sales.
• Difficulty and cost in protecting intellectual property and proprietary technologies, especially in foreign countries like China, could impair competitive ability.
• The price of common stock is volatile and may fluctuate significantly, leading to potential losses for stockholders.
• Future issuances and exercise of outstanding warrants (23.4 million shares) could dilute ownership interests of stockholders.

Future Outlook

The company expects ongoing macroeconomic and geopolitical issues, including inflation, supply chain challenges, high interest rates, and tariffs, to continue adversely impacting its business, gross margins, net income (loss), and cash from operations through at least fiscal year 2026. Reduced budgets and longer customer installation timelines in the U.S. are also expected to negatively affect net revenue through fiscal year 2026. The company believes its current cash and available debt facilities will be sufficient for operations for at least the next 12 months, but acknowledges uncertainty regarding compliance with debt covenants. A significant organizational, strategic, and operational transformation is underway, expected to be substantially completed by the fourth quarter of fiscal year 2026, aiming to increase operating margins and enhance agility.

Management Comments

• Management is carefully evaluating the liquidity position, communicating with and monitoring customers and suppliers, and reviewing near-term financial performance due to ongoing uncertainties.
• Management continues to evaluate operating expenses to conserve cash in light of the uncertain macroeconomic environment and assess real estate needs.
• The company believes its strategy in China, including the JV's local manufacturing and distribution of Accuray systems, will maximize both near and longer-term opportunities.
• Management expects that the business of customers and its own business will continue to be adversely impacted, directly or indirectly, by macroeconomic and geopolitical issues.

Industry Context

The company operates in the highly competitive and rapidly evolving medical device industry, specifically in non-invasive cancer treatment. It faces intense competition from larger, well-capitalized companies like Varian Medical Systems (a Siemens Healthineers company) and Elekta AB, which hold significant market share. The industry is also subject to rapid technological change, with new competitors and treatment approaches (e.g., MRI-guided radiotherapy, proton therapy, gene therapy) constantly emerging. Macroeconomic factors such as inflation, supply chain disruptions, and healthcare budget constraints are significant headwinds, impacting capital expenditure decisions by hospitals and treatment centers globally. The long sales cycles and high unit prices of radiation oncology systems make the industry particularly sensitive to economic volatility and reimbursement policy changes.

Comparison to Industry Standards

• The company's book-to-bill ratio of 1.1 for the quarter is below the industry indicator of 1.2, which generally signifies strong demand for products, suggesting weaker demand compared to optimal industry performance.
• The significant increase in net loss and decline in gross margin, coupled with a high effective interest rate on debt (23.8%), indicates financial performance below typical industry benchmarks for healthy, growing medical device companies, especially those with established product lines.
• The company's reliance on a joint venture in China, which saw a substantial decrease in product sales, highlights a vulnerability in a key growth market compared to competitors who might have more diversified or direct market access strategies in the region.

Management Changes

Corporate Governance

Legal Proceedings

• The company is involved in legal proceedings, including claims, investigations, and inquiries, arising in the ordinary course of its business.
• Management believes there are no probable and reasonably estimable material losses related to any current legal proceedings and claims as of September 30, 2025.
• Litigation is inherently unpredictable and subject to significant uncertainties, with potential for material impact on results if estimates and assumptions change or prove incorrect.

Related Party Transactions

• The joint venture (JV) in China, CNNC Accuray (Tianjin) Medical Technology Co. Ltd., is an equity method investment where the company owns a 49% interest.
• Accounts receivable from the JV were $9.6 million as of September 30, 2025, down from $28.5 million as of June 30, 2025.
• Other receivables from the JV were $359 thousand as of September 30, 2025.
• Sales of products to the JV were $8.8 million during the three months ended September 30, 2025, a significant decrease from $28.6 million in the prior year.
• Sales of services to the JV were $5.5 million during the three months ended September 30, 2025, up from $4.1 million in the prior year.
• Cost of revenue from sales to the JV was $9.5 million during the three months ended September 30, 2025, down from $20.9 million in the prior year.
• Charge backs to the JV related to research and development were $359 thousand during the three months ended September 30, 2025.
• The JV declared a $2.5 million dividend to the company in June 2025, which was paid in July 2025.
• The JV represented approximately 15% of total net revenue for the three months ended September 30, 2025, and approximately 17% of total accounts receivable as of September 30, 2025.

Stakeholder Impact

• **Shareholders:** Experience significant dilution risk from the exercise of outstanding warrants (23.4 million shares) and potential future equity issuances. The substantial net loss and declining stock price volatility could lead to losses.
• **Employees:** Approximately 3% of the global workforce was eliminated as part of a cost-saving initiative, impacting job security and morale. New management and a transformation plan could bring new opportunities or further changes.
• **Customers:** May face longer installation timelines and reduced capital deployment priority for radiotherapy equipment, potentially delaying access to new systems. Ongoing supply chain issues could affect product availability and service delivery.
• **Suppliers:** Continued supply chain challenges and inflationary pressures could impact demand for components and pricing negotiations.
• **Creditors:** The company has substantial indebtedness with a high effective interest rate on its Term Loan Facilities. While currently in compliance with covenants, macroeconomic uncertainties pose a risk to future compliance and the ability to repay debt.

Next Steps

• Substantially complete the cost-saving initiative, including workforce reduction, by the fourth quarter of fiscal year 2026.
• Implement the organizational, strategic, and operational transformation initiatives during the current fiscal year.
• Stephen La Neve will lead the company as President and CEO, with Steven F. Mayer providing consulting services as Transformation Board Sponsor for one year.
• Continue to critically review liquidity and anticipated capital requirements in light of macroeconomic conditions.
• Monitor compliance with covenants contained in the Financing Agreement.
• Pay the remaining $18.0 million balance of the 3.75% Convertible Senior Notes due June 1, 2026, using operating cash.
• Evaluate the impact of new accounting standards (ASU 2023-09 and ASU 2024-03) for future adoption.
• Continue to monitor recorded goodwill for indicators of impairment every fiscal quarter.

Key Dates

Recommendation

Accuray's Q1 results show a significant widening of net loss and a decline in revenue and gross profit, which are strong negative indicators. The high effective interest rate on debt and ongoing macroeconomic headwinds (inflation, supply chain, tariffs) present substantial financial challenges. However, the company has initiated a significant organizational transformation with new leadership, which could be a catalyst for future improvement. The positive operating cash flow for the quarter is also a notable improvement. Given the immediate poor financial performance balanced against the potential long-term benefits of the transformation and the current liquidity position, a 'hold' recommendation is appropriate. Investors should monitor the execution of the transformation plan, improvements in gross margins, and the impact of macroeconomic factors on future financial results before making further investment decisions.

Keywords

Radiation Therapy, Oncology Systems, Medical Devices, CyberKnife, TomoTherapy, Radixact, SEC Filing, 10-Q, Financial Results, Net Loss, Revenue Decline, Restructuring, Supply Chain, Tariffs, Debt, Warrants, Corporate Governance, Leadership Change, China Joint Venture, Healthcare Industry, Macroeconomic Risks